Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). Thi...

Full description

Saved in:

Bibliographic Details
Published in:	Neurology Vol. 78; no. 22; p. 1736
Main Authors:	Trampe, A K, Hemmelmann, C, Stroet, A, Haghikia, A, Hellwig, K, Wiendl, H, Goelz, S, Ziegler, A, Gold, R, Chan, A
Format:	Journal Article
Language:	English
Published:	United States 29.05.2012
Subjects:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Viral - blood Clinical Trials as Topic Cohort Studies Cross-Sectional Studies Female Germany - epidemiology Humans Immunosuppressive Agents - therapeutic use JC Virus - immunology Leukoencephalopathy, Progressive Multifocal - diagnosis Leukoencephalopathy, Progressive Multifocal - epidemiology Leukoencephalopathy, Progressive Multifocal - immunology Leukoencephalopathy, Progressive Multifocal - virology Longitudinal Studies Male Middle Aged Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - immunology Multiple Sclerosis - virology Natalizumab Predictive Value of Tests Retrospective Studies Risk Assessment Risk Factors Single-Blind Method Germany
ISSN:	1526-632X, 1526-632X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!